NCT03329690 (Clinical Trial/ DS-8201a – trastuzumab deruxtecan)

Study Title
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer (NCT03329690)

Trial Description
The primary purpose of this trial is to compare the efficacy and safety of DS-8201a (trastuzumab deruxtecan) and physician’s choice treatment in HER2-overexpressing advanced gastric or gastroesophageal junction adenocarcinoma patients who have progressed on two prior treatment regimens including fluoropyrimidine agent, platinum agent, and trastuzumab.

This trial is sponsored by Daiichi Sankyo Co., Ltd.®.

Study Data

  • Condition: Neoplasm, Gastrointestinal
  • Interventions:
    • Drugs used in this trial
      • DS-8201a
  • Phase: II
  • Enrollment: 220
  • Start: October 2017
  • Estimated Completion: December 2019
  • Last verified: December 2017
  • Last Updated: December 2017

Study Schematic

Click here to Return to Drug map

Last Editorial review: January 2018
Information based on (NIH/NCI) and other sources.